Status:
UNKNOWN
Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension
Lead Sponsor:
Pacific Pharmaceuticals
Conditions:
Essential Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess which drug is more effective of Ramiprin®(ramipril) and Tritace®(ramipril) in the Treatment of Essential Hypertension
Eligibility Criteria
Inclusion
- mild and moderate essential hypertension (90mmHg≤DBP≤110mmHg)
Exclusion
- 180mmHg≤SBP
- If differences greater than 20mmHg for SBP and 10mmHg for DBP between both arms are present on 3 consecutive readings
- If differences greater than 20mmHg for SBP and 10mmHg for DBP are present on 3 consecutive readings
- impaired hepatic function
- imapaired renal function
- angioedema
- aortic valvular stenosis or obstrcutive ejection disorder
- primary hyperaldosteronism
- renal transplantation, bilateral renal artery stenosis or unilateral stenosis in a single kidney, hemodialysis
- severe respiratory disease
- congestive heart failure( New York Association functional class Ⅲ or Ⅳ)
- malignant hypertension
- labile angina pectoris or myocardial infarction in the last 3 months before study entry
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
End Date :
June 1 2007
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT00366119
Start Date
June 1 2006
End Date
June 1 2007
Last Update
March 9 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, 28 Yeongeon-dong, Jongno-gu, South Korea, 110-744